Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.
Lindemann K, Kristensen G, Mirza MR, Davies L, Hilpert F, Romero I, Ayhan A, Burges A, Rubio MJ, Raspagliesi F, Huizing M, Creemers GJ, Lykka M, Lee CK, Gebski V, Pujade-Lauraine E. Lindemann K, et al. Among authors: burges a. Ann Oncol. 2016 Aug;27(8):1505-10. doi: 10.1093/annonc/mdw238. Epub 2016 Jul 11. Ann Oncol. 2016. PMID: 27407100 Free article. Clinical Trial.
Publisher Erratum: Langer Leidensweg bei Endometriose.
Beyer S, Trillsch F, Kost B, Burges A, Mahner S, Kolben T. Beyer S, et al. Among authors: burges a. MMW Fortschr Med. 2023 Feb;165(2):66. doi: 10.1007/s15006-023-2298-0. MMW Fortschr Med. 2023. PMID: 36703076 German. No abstract available.
Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group.
Hilpert F, Stähle A, Tomé O, Burges A, Rossner D, Späthe K, Heilmann V, Richter B, du Bois A; Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group. Hilpert F, et al. Among authors: burges a. Support Care Cancer. 2005 Oct;13(10):797-805. doi: 10.1007/s00520-005-0782-y. Epub 2005 Jul 16. Support Care Cancer. 2005. PMID: 16025262 Clinical Trial.
Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR).
du Bois A, Burges A, Meier W, Pfisterer J, Schmalfeldt B, Richter B, Jackisch C, Staehle A, Kimmig R, Elser G; Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom. du Bois A, et al. Among authors: burges a. Ann Oncol. 2006 Jan;17(1):93-6. doi: 10.1093/annonc/mdj032. Epub 2005 Nov 9. Ann Oncol. 2006. PMID: 16282248 Free article. Clinical Trial.
Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis.
Harter P, Hahmann M, Lueck HJ, Poelcher M, Wimberger P, Ortmann O, Canzler U, Richter B, Wagner U, Hasenburg A, Burges A, Loibl S, Meier W, Huober J, Fink D, Schroeder W, Muenstedt K, Schmalfeldt B, Emons G, du Bois A. Harter P, et al. Among authors: burges a. Ann Surg Oncol. 2009 May;16(5):1324-30. doi: 10.1245/s10434-009-0357-0. Epub 2009 Feb 19. Ann Surg Oncol. 2009. PMID: 19225844
Significance of serum CA125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up.
van Dalen A, Favier J, Hallensleben E, Burges A, Stieber P, de Bruijn HW, Fink D, Ferrero A, McGing P, Harlozinska A, Kainz Ch, Markowska J, Molina R, Sturgeon C, Bowman A, Einarsson R, Goike H. van Dalen A, et al. Among authors: burges a. Eur J Gynaecol Oncol. 2009;30(6):609-15. Eur J Gynaecol Oncol. 2009. PMID: 20099488
Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).
Wimberger P, Wehling M, Lehmann N, Kimmig R, Schmalfeldt B, Burges A, Harter P, Pfisterer J, du Bois A. Wimberger P, et al. Among authors: burges a. Ann Surg Oncol. 2010 Jun;17(6):1642-8. doi: 10.1245/s10434-010-0964-9. Epub 2010 Feb 18. Ann Surg Oncol. 2010. PMID: 20165986
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.
du Bois A, Herrstedt J, Hardy-Bessard AC, Müller HH, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Weber B, Kurzeder C, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, Jackisch C, Sehouli J. du Bois A, et al. Among authors: burges a. J Clin Oncol. 2010 Sep 20;28(27):4162-9. doi: 10.1200/JCO.2009.27.4696. Epub 2010 Aug 23. J Clin Oncol. 2010. PMID: 20733132 Clinical Trial.
Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.
Lee CK, Simes RJ, Brown C, Lord S, Wagner U, Plante M, Vergote I, Pisano C, Parma G, Burges A, Bourgeois H, Högberg T, Bentley J, Angleitner-Boubenizek L, Ferrero A, Richter B, Hirte H, Gebski V, Pfisterer J, Pujade-Lauraine E, Friedlander M. Lee CK, et al. Among authors: burges a. Br J Cancer. 2011 Oct 11;105(8):1144-50. doi: 10.1038/bjc.2011.364. Epub 2011 Sep 13. Br J Cancer. 2011. PMID: 21915127 Free PMC article.
179 results